Evaluation of antiangiogenic and muco-modulatory effects of polymeric nanoparticles based on chitosan, hyaluronic acid and hydroxypropylmethylcellulose phthalate containing bevacizumab drug for potential treatment of colorectal cancer

• Grant number: 21/09110-0
• Support Opportunities: Scholarships in Brazil - Master
• Start date: March 01, 2022
• End date: September 30, 2023
• Field of knowledge: Health Sciences - Pharmacy - Pharmaceutical Technology
• Principal Investigator: Maria Palmira Daflon Gremião
• Grantee: Aline Franciane Leão
• Host Institution: Faculdade de Ciências Farmacêuticas (FCFAR). Universidade Estadual Paulista (UNESP). Campus de Araraquara. Araraquara , SP, Brazil
• Associated scholarship(s): 22/05904-4 - Evaluation of biological performance of bevacizumab loaded polymeric nanostructure intended colorectal cancer treatment, BE.EP.MS

Abstract

Colorectal cancer (CC) ranks the third among the most common worldwide, which reinforces the urgent need for more effective or alternative treatments. A special emphasis regarding treatment modalities should consider drugs that can act against the angiogenesis process, which is directly related to tumor development. Based on nanotechnology tools, the development of polymeric nanoparticles (NPs) based on polysaccharides for oral administration has been promising for the treatment of CC. However, there are still some gaps that need to be overcoming the inherent barriers of this route of administration. The knowledge of how to manipulate the nanosystems properties and physicochemical characteristics intended specific biological performance compose the most recent challenge in the pharmaceutical nanotechnology area. Besides, the use of more biorelevant models to evaluate nanosystems' biological performance may have gained great importance allowing a deeper understanding of the NPs mechanism of action mechanism at the nano-bio interface. Therefore, this scientific project proposes the evaluation of NPs based on chitosan (QS), hyaluronic acid (HA) and hydroxypropylmethylcellulose phthalate on the antiangiogenic capacity of bevacizumab (BVZ), using the membrane embryo chorioallantoic (CAM) model. Additionally, the muco-modulatory capacity of these systems will be detailed investigated. (AU)